Short answer
Zenas BioPharma, Inc. (ZBIO) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 8.01 (Other Events). New ATM program permits up to $200 million in additional common-stock sales.
Zenas BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- New ATM program permits up to $200 million in additional common-stock sales
- Prior $200 million ATM terminated after approximately $153.2 million sold
- Approximately $46.8 million remained unsold under the prior prospectus at termination
- Potential equity issuance creates dilution risk but provides financing flexibility for operations and development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zenas BioPharma, Inc. 8-K filings
Get the next ZBIO 8-K as it lands
Follow ZBIO for push alerts, or ask the research agent what this filing means.